View More Recent Stories

Jul 26, 2017 06:40PM FDA Approves Eisai's FYCOMPA® (perampanel) for Use as Monotherapy for the Treatment of Partial-Onset Seizures
Jul 11, 2017 10:00AM Morphotek Announces Publication Uncovering One Of The Mechanisms By Which The Tumor-Produced CA125 Protein Suppresses Immune-Mediated Killing Via Farletuzumab
Apr 26, 2017 10:00AM Morphotek To Present Its Proprietary RESPECT™ Antibody Drug Conjugate (ADC) Technology At The Upcoming 13th Annual PEGS Summit In Boston
Apr 3, 2017 09:00AM Morphotek Launches Antibody Drug Conjugate Services Business
Mar 28, 2017 10:00AM Morphotek to Present Three Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting 2017
Mar 23, 2017 08:06AM Eisai to Launch New Medikidz Epilepsy Comic Book at the National Walk for Epilepsy
Mar 22, 2017 10:00AM Morphotek And Sandy Rollman Ovarian Cancer Foundation Launch Educational Resource On Clinical Trials
Dec 19, 2016 01:32PM Eisai and Arena (ARNA) Announce BELVIQ Approval in Brazil
Dec 19, 2016 01:30PM Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil
Dec 12, 2016 07:01AM Merck (MRK) and Eisai Reports Encourating Phase 1b/2 KEYTRUDA/HALAVEN Combo Results
Dec 12, 2016 07:00AM Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck's KEYTRUDA® (pembrolizumab) and Eisai's HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer P
Oct 26, 2016 02:27PM Eisai's LENVIMA® (lenvatinib) Nominated for Galien Foundation's Best Pharmaceutical Product
Oct 26, 2016 08:10AM Eisai Launches New Medikidz Epilepsy Comic Book in Conjunction with Lennox-Gastaut Syndrome (LGS) Awareness Day
Oct 3, 2016 09:00AM Morphotek and Eurofarma Laboratórios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America
Oct 3, 2016 08:07AM Arena Pharma (ARNA), Eisai Announces Availability of New Once-Daily BELVIQ XR
Oct 3, 2016 08:06AM Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets
Sep 22, 2016 02:00PM New #ThisIsMBC Campaign Seeks to Raise Awareness of Metastatic Breast Cancer by Encouraging People with This Rarely Discussed, Deadly Stage of the Disease to Share Their Experiences
Sep 21, 2016 02:00PM Myths and Truths About Thyroid Cancer Educational Initiative Honors Thyroid Cancer Awareness Month with Launch of New #TruthAboutTC Social Media Challenge
Sep 15, 2016 08:00AM Eisai Establishes AiM Institute to Discover Human Biology Driven Precision Medicines
Sep 13, 2016 10:00AM Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center To Study Immunosuppressive Effects Of Tumor Shed Antigens To Improve Future Patient Therapies
Jun 20, 2016 02:08AM AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease
Jun 1, 2016 06:17AM AbbVie GK (ABBV), Eisai Begin co-Promotion of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Field of Gastrointestinal Disease
Jun 1, 2016 01:19AM AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Field of Gastrointestinal Disease
Sep 24, 2015 08:15AM Eisai Expands Magnolia Meals at Home® Program to Help People Living with Thyroid Cancer
Sep 15, 2015 08:15AM New Myths and Truths About Thyroid Cancer Education Initiative Aims to Shine a Light on the Truths about Thyroid Cancer
May 28, 2015 09:10PM AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA, a Fully Human Anti-TNF-alpha Monoclonal Antibody, in the Treatment of Ankylosing Spondylitis
View More Recent Stories